Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics N.V (PRQR) Accounts Payables: 2021-2024

  • ProQR Therapeutics N.V's Accounts Payables fell 98.97% to $17,098 in Q4 2024 from the same period last year, while for Dec 2024 it was $17,098, marking a year-over-year decrease of 98.97%. This contributed to the annual value of $17,098 for FY2024, which is 98.97% down from last year.
  • As of Q4 2024, ProQR Therapeutics N.V's Accounts Payables stood at $17,098, which was down 98.97% from $1.7 million recorded in Q4 2023.
  • ProQR Therapeutics N.V's 5-year Accounts Payables high stood at $1.7 million for Q4 2023, and its period low was $17,098 during Q4 2024.
  • For the 3-year period, ProQR Therapeutics N.V's Accounts Payables averaged around $691,686, with its median value being $399,937 (2022).
  • Its Accounts Payables has fluctuated over the past 5 years, first spiked by 314.57% in 2023, then plummeted by 98.97% in 2024.
  • Over the past 4 years, ProQR Therapeutics N.V's Accounts Payables (Quarterly) stood at $218,498 in 2021, then soared by 83.04% to $399,937 in 2022, then surged by 314.57% to $1.7 million in 2023, then crashed by 98.97% to $17,098 in 2024.
  • Its Accounts Payables was $17,098 in Q4 2024, compared to $1.7 million in Q4 2023 and $399,937 in Q4 2022.